Atrial flutter – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:53 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Atrial flutter – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Ticagrelor and Rivaroxaban in Patients with Atrial Fibrillation After Coronary Stent Surgery https://clinicaltrials.eu/trial/study-on-the-effects-of-ticagrelor-and-rivaroxaban-in-patients-with-atrial-fibrillation-after-coronary-stent-surgery/ Wed, 29 Apr 2026 15:00:40 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ticagrelor-and-rivaroxaban-in-patients-with-atrial-fibrillation-after-coronary-stent-surgery/ This clinical trial is focused on patients with atrial fibrillation, a condition where the heart beats irregularly. These patients have undergone a procedure called percutaneous coronary intervention (PCI), which is a type of surgery to restore blood flow to the heart using a stent. The study is investigating the use of a single drug that prevents blood clots, known as a P2Y12 inhibitor, followed by a direct-acting oral anticoagulant (DOAC). The medications being studied include rivaroxaban, ticagrelor, edoxaban, dabigatran, apixaban, clopidogrel, prasugrel, and acetylsalicylic acid.

The purpose of the study is to assess the safety and effectiveness of this treatment approach compared to the current standard treatment, which involves using a combination of medications to prevent blood clots. The study will follow patients for a period of 15 months to monitor for any major heart or brain events, such as heart attacks or strokes, as well as any significant bleeding events. The trial will also compare the outcomes of using the P2Y12 inhibitor alone for one month, followed by the DOAC alone for a longer period, against the standard treatment that involves multiple medications over several months.

Participants in the study will receive either the new treatment approach or the standard treatment. The study will help determine if the new approach is as safe and effective as the current standard. This research is important for improving treatment options for patients with atrial fibrillation who have undergone PCI, potentially leading to better health outcomes and fewer complications.

]]>